BioAlliance undeterred by move to shelve trial

France's BioAlliance Pharma says it's full steam ahead for its strategy to acquire complementary products for oncology and HIV, despite Immtech's decision to end a trial for pafuramidine--a program BioAlliance is partnered on. Immtech announced late Friday that it is shelving a safety study of pafuramidine after seeing reports of liver and kidney abnormalities. The drug was being tested for pneumonia in HIV patients and for African sleeping sickness.

- here's the release
- read the AFX report

Related Articles:
Immtech announce Phase III analysis. Report
Par strikes $65M licensing deal for antifungal therapy. Report